🔎 Trials Near Me

Beranda › Tumor Otak › Illinois

Uji klinis Tumor Otak di Illinois

14 studi untuk Tumor Otak mencari peserta di lokasi di Illinois.

Kota di Illinois

Teks studi resmi (Bahasa Inggris)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • Saint Anthony's Health, Alton
  • Rush - Copley Medical Center, Aurora
  • Illinois CancerCare-Bloomington, Bloomington
  • dan 33 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04511013

Frameless Stereotactic Radiosurgery for Intact Brain Metastases

  • University of Chicago, Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02747303

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • University of Chicago, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • Carle Cancer Center, Urbana
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05386108

Targeted Pediatric High-Grade Glioma Therapy

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

  • Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06764940

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

  • Lurie Children's Hospital, Chicago
Menerima pesertaFase 2
Usia 1 hingga 26 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07680439

REMASTer: REcurrent Brain Metastases After SRS Trial

  • University of Chicago, Chicago
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Jun 2026 · NCT05124912

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

  • Decatur Memorial Hospital, Decatur
  • HSHS Saint Elizabeth's Hospital, O'Fallon
  • Methodist Medical Center of Illinois, Peoria
  • dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT03550391

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Northwestern Memorial Hospital, Chicago
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06810544

Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery

  • University of Illinois at Chicago, Chicago
Menerima peserta
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 12 Nov 2025 · NCT07111182

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • John H Stroger Jr Hospital of Cook County, Chicago
  • Decatur Memorial Hospital, Decatur
  • Loyola University Medical Center, Maywood
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT03418961

Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.